Education & training
Résumé des recommandations du CCI concernant les programmes d'immunisation contre le zona
Résumé des recommandations du Comité canadien sur l'immunisation concernant les programmes d'immunisation contre le virus du papillome humain
En fonction des données scientifiques, le Comité consultatif national de l’immunisation (CCNI) recommande désormais l’immunisation contre le VPH chez les hommes et les femmes âgés de 9 à 26 ans pour la prévention de la maladie liée au VPH. En réponse aux indications élargies du vaccin quadrivalent contre le VPH et compte tenu de l’introduction d’un nouveau vaccin bivalent contre le VPH, le Comité canadien sur l’immunisation (CCI) s’est penché sur les considérations liées aux programmes du vaccin contre le VPH et la pertinence de l’inclure dans les calendriers de vaccination systématique des provinces/territoires. Le présent article est un résumé des recommandations complètes du CCI en ce qui concerne le VPH.
Statement on the Booster for 4-6-Year-Olds for Protection against Pertussis
The purpose of this statement is to review the literature relevant to the 4- to 6-year-old preschool booster immunization and provide updated recommendations as required. Current recommendations for the 4- to 6-year-old preschool booster include additional doses of diphtheria, tetanus, acellular pertussis and polio containing vaccine.
Storage and Handling of Vaccines: The Cold Chain
Webinar.
Summary of Canadian Immunization Committee (CIC) Recommendations for Human Papillomavirus Immunization Programs
On the basis of scientific evidence, the National Advisory Committee on Immunization (NACI) now recommends HPV immunization for males and females between 9 and 26 years of age for the prevention of HPV disease. In response to expanded indications for the quadrivalent HPV vaccine, as well as with the introduction of a new bivalent HPV vaccine, the Canadian Immunization Committee (CIC) considered the programmatic issues of the HPV vaccines and their appropriateness for inclusion in provincial and territorial routine immunization schedules. This document is a brief summary of the full CIC HPV recommendations.
Summary of the CIC Recommendations for zoster immunization programs
Surveillance accrue des méningococcies invasives au Canada, 2006-2011
L’objectif du présent rapport est de décrire l’épidémiologie de la méningococcie invasive au Canada de 2006 à 2011.
The Recommended Use of the Multicomponent Meningococcal B (4CMenB) Vaccine in Canada
The NACI Statement, presented as Part 1, and the programmatic chapters, presented as Part 2, have been combined together and are considered the Common Guidance for the recommended use of the multicomponent meningococcal B (4CMenB) vaccine in Canada.
Update on the Use of Herpes Zoster Vaccine
Since the development of the 2010 statement, new data has been published with regards to the administration and safety of herpes zoster vaccine. n order to inform the recommendations of the National Advisory Committee on Immunization (NACI) made in this update, a systematic review of the literature was undertaken. This review focused on emerging literature since the previous statement as well as specific areas highlighted for review. Articles were obtained using a PubMed search from August 31, 2008 to September 30, 2012. Recommendations and llevels of evidence evaluations were agreed to by consensus of NACI members and were based on previously published NACI guidelines.
Update on the Use of Pneumococcal Vaccines: Addition of Asthma as a High-Risk Condition
Current evidence indicates that asthma is a risk factor for invasive pneumococcal disease, even in the absence of prolonged systemic corticosteroid use or COPD. Pneumococcal infection can cause severe disease. The most effective way to prevent these infections is through immunization.